Oppenheimer Sticks to Their Buy Rating for Sutro Biopharma (STRO)

In a report released today, Jay Olson from Oppenheimer maintained a Buy rating on Sutro Biopharma (STRO – Research Report), with a price target of $10.00. The company’s shares closed yesterday at $4.34.

Olson covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, ACADIA Pharmaceuticals, and Incyte. According to TipRanks, Olson has an average return of 17.8% and a 43.67% success rate on recommended stocks.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Sutro Biopharma with a $12.00 average price target, which is a 176.50% upside from current levels. In a report released yesterday, Piper Sandler also reiterated a Buy rating on the stock with a $11.00 price target.

STRO market cap is currently $355M and has a P/E ratio of -2.30.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Sutro Biopharma (STRO) Company Description:

Sutro Biopharma Inc. engages in the drug discovery, development and manufacturing of pharmaceutical products. Its products technologies include XpressCF, anti-body drug conjugates, bispecifics & engineered antibodies and cGMP facility. The company was founded by James R. Swartz and Sutanto Widjaja in June 2003 and is headquartered in South San Francisco, CA.